ascopubs.org8d
State of Professional Well-Being, Satisfaction, and Career Plans Among US Oncologists in 2023
Oncologists in 2023 are experiencing higher rates of burnout compared with a decade ago. System-based interventions to reduce burnout are necessary to maintaining an adequate workforce to provide care ...
ascopubs.org10d
Performance of a blood-based test for colorectal cancer screening adjusted to the US census age and sex distribution.
Final analysis of modified (m)-FOLFOXIRI plus cetuximab versus bevacizumab for RAS wild-type and left-sided metastatic colorectal cancer: The DEEPER trial (JACCRO CC-13). Single-cycle neoadjuvant ...
ascopubs.org11d
Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma
Finding the Right Partner: Triplet Therapy for First-Line Advanced Biliary Tract Cancers BV combined with Len + R demonstrated significant improvements in overall survival (OS; 37% reduced risk of ...
ascopubs.org8d
Key Strategies to Promote Professional Wellness and Reduce Burnout in Oncology Clinicians
Burnout in oncologists has been increasing, especially after the COVID-19 pandemic. This is concerning because burnout can have both personal and professional repercussions, as well as a negative ...
ascopubs.org21d
Toward a Computable Phenotype for Determining Eligibility of Lung Cancer Screening Using Electronic Health Records
Novel Use and Value of Contrast-Enhanced Susceptibility-Weighted Imaging Morphologic and Radiomic Features in Predicting Extremity Soft Tissue Undifferentiated Pleomorphic Sarcoma Treatment Response ...
ascopubs.org24d
Supervised Exercise for Patients With Metastatic Breast Cancer: A Cost-Utility Analysis Alongside the PREFERABLE-EFFECT Randomized Controlled Trial
Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Results From the Prospective BladderPath Trial A cost-utility analysis was performed ...
ascopubs.org10d
MUC5AC levels as predictors of adjuvant therapy outcomes in pancreatic ductal adenocarcinoma: A study of post-surgical gemcitabine-based regimens.
Genomic analysis of paired primary and metastatic pancreatic ductal adenocarcinoma tumors.
ascopubs.org10d
A novel immune-based score and its immune contexture exploration in colorectal cancer.
PK/PD analyses of circulating tumor DNA (ctDNA) in patients with metastatic colorectal cancer (mCRC) treated with telisotuzumab adizutecan (ABBV-400). This is an ASCO Meeting Abstract from the 2025 ...
ascopubs.org10d
A first-in-human phase I trial with antibody drug conjugate ADCT-701 in neuroendocrine tumors and carcinomas.
Comparative outcomes of neuroendocrine tumors in the historically underserved population of Bronx, NY: Montefiore Einstein Comprehensive Cancer Center. Pamrevlumab ...
ascopubs.org10d
Nirogacestat in patients with desmoid tumors and mutations of adenomatous polyposis coli (APC): Findings from the DeFi trial.
Total neoadjuvant therapy with FOLFOX plus bevacizumab and short-course radiotherapy for Ras mutant, high-risk, locally advanced rectal cancer: The TRAINER trial. Phase Ib study of gevokizumab (GEVO) ...
ascopubs.org10d
Role of cfDNA and DNA integrity index (DII) in colon cancer in response to surgery.
A comprehensive molecular and clinical study of patients with young-onset CRC. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This abstract does not include a ...
ascopubs.org9d
Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors
Botensilimab (Fc-enhanced anti–cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti–PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas Larotrectinib is a ...